01
Mar
Nct 01121224) was a multicenter, randomized clinical trial designed to address the limitations of prior studies and provide a contemporary robust assessment of optimal stent choice for svg pci. At 12 months, the incidence of target vessel failure (composite of cardiac death, target vessel myocardial infarction, or target.
Cas pubmed article google scholar 35.
Bare metal stents vs drug eluting stents. Nct 01121224) was a multicenter, randomized clinical trial designed to address the limitations of prior studies and provide a contemporary robust assessment of optimal stent choice for svg pci. Patients who received at least one des (n = 4754) were compared with those who received only bare metal stents (bms) (n = 4956) at the index procedure. The drug‐eluting stents vs bare‐metal stents in saphenous vein graft angioplasty trial (diva;
Background while a growing number of reports offer evidence for the potential of drug eluting stents (des) in treating atherosclerotic stenosis of the extracranial vertebral artery, their efficacy when compared with bare metal stents (bms) is uncertain due to the lack of a large prospective randomized trial. The composite endpoint of death, myocardial infarction, or target lesion revascularization is represented as a function of time and favors des. The objective was to obtain mechanical parameters for direct comparison of bms and des.
Cas pubmed article google scholar 35. Although dual antiplatelet therapy (dapt) beyond one year provides ischemic event protection following des, ischemic event risk is perceived to be less following bms and the. Combined outcome of death or myocardial infarction (mi) showed no difference for des vs.
Most studies do not distinguish between des and bms with respect to their mechanical performance. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: Most studies do not distinguish between des and bms with respect to their mechanical performance.
A randomised controlled superiority trial. At 12 months, the incidence of target vessel failure (composite of cardiac death, target vessel myocardial infarction, or target. Clinical trials have confirmed a reduction of as much as 50 to 70 % in target lesion revascularization by des compared to bms.
They may, however, be more prone than bare metal stents to late (beyond 1 year) and sudden coronary artery occlusion. Stents with drug elution technology (des) were developed to reduce the relatively high rate of isr and subsequent repeat revascularization seen with bms.